Treatment delivery and results: ABVD or COPP/ ABVD in randomized controlled trials.
| . | U.S.Intergroup ABVD N = 412 . | UK LY09 ABVD N = 406 . | Italian Intergroup ABVD N = 122 . | GHSG HD9 COPP/ABVD N = 260 . |
|---|---|---|---|---|
| *See text for explanation; FFS=78%. | ||||
| †Extrapolated from published survival curves. | ||||
| Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; COPP, cyclophosphamide, vincristine, prednisone, procarbazine; FFS, failure-free survival; IPS, International Prognostic Score; OS, overall survival; NR, not reported | ||||
| FFS, % | 63 (5 y) | 75 (3 y) | 85* (5 y) | 69 (5 y) |
| FFS, % | ||||
| IPS 0,1 | 76, 72 | ~86† | NA | 79 |
| IPS 2,3 | 81, 69 | ~75† | NA | 67 |
| IPS 4–7 | 64, 67 | ~74† | NA | 59 |
| OS, % | 81 (5 y) | 90 (3 y) | 90 (5 y) | 83 (5 y) |
| Reported treatment delivery | NR | > 0.80 relative dose intensity | 0.83 relative dose intensity | Median treatment duration 46.3 wk vs 30 wk planned |
| Irradiated, % | 0 | 38 | 76 | 64 |
| . | U.S.Intergroup ABVD N = 412 . | UK LY09 ABVD N = 406 . | Italian Intergroup ABVD N = 122 . | GHSG HD9 COPP/ABVD N = 260 . |
|---|---|---|---|---|
| *See text for explanation; FFS=78%. | ||||
| †Extrapolated from published survival curves. | ||||
| Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; COPP, cyclophosphamide, vincristine, prednisone, procarbazine; FFS, failure-free survival; IPS, International Prognostic Score; OS, overall survival; NR, not reported | ||||
| FFS, % | 63 (5 y) | 75 (3 y) | 85* (5 y) | 69 (5 y) |
| FFS, % | ||||
| IPS 0,1 | 76, 72 | ~86† | NA | 79 |
| IPS 2,3 | 81, 69 | ~75† | NA | 67 |
| IPS 4–7 | 64, 67 | ~74† | NA | 59 |
| OS, % | 81 (5 y) | 90 (3 y) | 90 (5 y) | 83 (5 y) |
| Reported treatment delivery | NR | > 0.80 relative dose intensity | 0.83 relative dose intensity | Median treatment duration 46.3 wk vs 30 wk planned |
| Irradiated, % | 0 | 38 | 76 | 64 |